ELIZABETH MUSCATIELLO: Open Payments
NPI 1841672136 · BURLINGTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$650 in 31 payments from 14 companies in 2025. Trend: 2023 $477 · 2024 $580 · 2025 $650
Food & beverage: $650
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $104 |
| PFIZER INC. | 3 | $69 |
| Gilead Sciences, Inc. | 3 | $67 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| GENZYME CORPORATION | 1 | $30 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
Products named: ENTYVIO, RINVOQ, LINZESS, DUPIXENT, XIFAXAN, XELJANZ, GIVLAARI, CREON.
Industry payments across MA — which companies pay providers there.
